EIS1 Antibody

What is the EIS1/ICE1 protein and why is it important for research?

EIS1/ICE1 (interactor of little elongation complex ELL subunit 1) is a nuclear protein that functions as a component of the little elongation complex (LEC). This complex plays a crucial role in regulating small nuclear RNA (snRNA) gene transcription by RNA polymerase II and III. The human canonical protein consists of 2266 amino acid residues with a molecular weight of approximately 247.9 kDa. Understanding EIS1/ICE1 function is important for research into transcriptional regulation and nuclear processes .

Research methodology for investigating EIS1/ICE1 typically involves:

• Nuclear fractionation to isolate the protein

• Co-immunoprecipitation studies to identify interacting partners

• ChIP-seq analysis to determine genomic binding sites

• Functional assays measuring snRNA transcription rates

What types of EIS1/ICE1 antibodies are available for research applications?

EIS1/ICE1 antibodies are available in multiple formats to accommodate various experimental needs:

Commercially available antibodies target various epitopes across the protein, with most showing reactivity to human EIS1/ICE1, though antibodies recognizing orthologs from model organisms including Drosophila are also available .

How do I validate the specificity of an EIS1/ICE1 antibody?

Validation of EIS1/ICE1 antibody specificity requires a multi-step approach:

• Western blot analysis: Confirm a single band at the expected molecular weight (approximately 248 kDa for human EIS1/ICE1)

• siRNA knockdown: Compare antibody signal between control and EIS1/ICE1-depleted samples

• Recombinant protein competition: Pre-incubate antibody with purified EIS1/ICE1 protein before application

• Cross-reactivity assessment: Test against related proteins, particularly other components of the LEC complex

• Immunoprecipitation followed by mass spectrometry: Confirm peptide sequences match EIS1/ICE1

For nuclear proteins like EIS1/ICE1, proper cellular fractionation is critical during validation to ensure accurate results. Additionally, comparison between multiple antibodies targeting different epitopes can provide stronger validation of specificity .

How should I optimize immunoprecipitation protocols for EIS1/ICE1 protein complexes?

Optimizing immunoprecipitation of EIS1/ICE1 requires careful consideration of the nuclear localization and complex formation properties of the protein:

• Nuclear extraction optimization:

  • Use gentle detergents (0.1-0.3% NP-40) for initial cell lysis

  • Apply high-salt buffer (300-400 mM NaCl) for nuclear extraction

  • Consider sonication (3-5 short pulses) for chromatin-bound protein release

• Crosslinking considerations:

  • For transient interactions: 1-2% formaldehyde, 10 minutes at room temperature

  • For stable complexes: No crosslinking or DSP (dithiobis(succinimidyl propionate)) at 1-2 mM

• Antibody binding optimization:

  • Test multiple antibody concentrations (1-5 μg per mg of nuclear extract)

  • Extend incubation time (overnight at 4°C with gentle rotation)

  • Compare different bead types (Protein A/G, magnetic vs. agarose)

• Washing stringency balance:

  • Begin with lower stringency (150 mM NaCl, 0.1% Triton X-100)

  • Gradually increase to maintain specific interactions while reducing background

When analyzing results, consider that EIS1/ICE1 functions in a multi-protein complex, so detection of interacting partners (such as ELL) can serve as positive controls for successful immunoprecipitation .

What are the critical parameters for optimizing Western blot detection of EIS1/ICE1?

Western blot detection of EIS1/ICE1 presents specific challenges due to its high molecular weight (248 kDa) and nuclear localization:

• Sample preparation optimization:

  • Nuclear extraction protocols are preferred over whole cell lysates

  • Include phosphatase inhibitors (1 mM sodium orthovanadate, 5 mM sodium fluoride)

  • Use fresh samples when possible, as freeze-thaw cycles can degrade high molecular weight proteins

• Gel electrophoresis parameters:

  • Use low percentage gels (6-8% acrylamide) for better resolution of high molecular weight proteins

  • Extended running time (30-40% longer than standard protocols)

  • Consider gradient gels (4-12%) for improved separation

• Transfer conditions for high molecular weight proteins:

  • Wet transfer at low voltage (25-30V) overnight at 4°C

  • Add SDS (0.1%) to transfer buffer to improve elution of large proteins

  • Use PVDF membrane (0.45 μm pore size) rather than nitrocellulose

• Detection optimization:

  • Extended primary antibody incubation (overnight at 4°C at 1:500-1:1000 dilution)

  • Signal enhancement systems for low abundance detection

  • Consider fluorescent secondary antibodies for better quantification

When troubleshooting, incomplete transfer is a common issue with high molecular weight proteins like EIS1/ICE1, so verify transfer efficiency with reversible protein stains before blocking .

How can I design ChIP-seq experiments to study EIS1/ICE1 binding to chromatin?

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) for EIS1/ICE1 requires careful optimization due to its role in transcriptional regulation:

• Crosslinking optimization:

  • Standard formaldehyde crosslinking (1%, 10 minutes) may be insufficient

  • Consider dual crosslinking: DSG (disuccinimidyl glutarate, 2 mM, 45 minutes) followed by formaldehyde

  • Test crosslinking times to balance efficiency and reversibility

• Chromatin fragmentation parameters:

  • Target fragment size: 200-300 bp for optimal resolution

  • Sonication calibration: 10-15 cycles (30 seconds on/30 seconds off)

  • Enzymatic digestion alternative: Micrococcal nuclease treatment (5-10 units/ml, 10 minutes at 37°C)

• Immunoprecipitation conditions:

  • Antibody selection: ChIP-grade antibodies with validated target specificity

  • Pre-clearing: Critical to reduce background, especially for nuclear factors

  • Controls: Include IgG negative control and positive control for known snRNA gene regions

• Bioinformatic analysis considerations:

  • Peak calling algorithms optimized for transcription factors

  • Motif analysis to identify binding sequences

  • Integration with RNA-seq data to correlate binding with transcriptional outcomes

For EIS1/ICE1 ChIP-seq specifically, focus analysis on snRNA genes and their promoter regions, as these are known sites of LEC complex activity. Compare results with ChIP-seq data for other LEC complex components to identify co-occupied regions .

How do I address inconsistent EIS1/ICE1 antibody performance across different applications?

Inconsistent antibody performance across applications often stems from different epitope accessibility requirements:

• Application-specific epitope availability:

  • For Western blot: Denatured epitopes may be exposed differently than in native applications

  • For IHC/ICC: Fixation methods dramatically affect epitope accessibility

  • For IP: Conformational epitopes may be critical for binding in solution

• Methodological troubleshooting approaches:

  • Epitope mapping: Test multiple antibodies targeting different regions

  • Fixation comparison: Test multiple fixation methods for IHC/ICC applications

  • Denaturation controls: Compare native vs. denatured IP conditions

• Antibody validation strategy:

  • Create application-specific validation panels

  • Test multiple antibody concentrations for each application

  • Consider developing application-specific positive controls

• Protocol modifications based on application:

When experiencing inconsistent results, systematically document conditions and create a decision tree for protocol modifications based on specific failure patterns .

What are the most common causes of background when using EIS1/ICE1 antibodies, and how can they be mitigated?

Background issues with EIS1/ICE1 antibodies can arise from several sources and require specific mitigation strategies:

• Non-specific antibody binding:

  • Increase blocking time and concentration (5% BSA or 5% milk, 2 hours at room temperature)

  • Pre-adsorb antibody with cell/tissue lysate from a species different from the target

  • Titrate antibody to find optimal concentration (typically 0.5-2 μg/ml for most applications)

• Cross-reactivity with related proteins:

  • Use monoclonal antibodies for increased specificity

  • Validate with knockout/knockdown controls

  • Perform peptide competition assays to confirm specificity

• Sample preparation artifacts:

  • Optimize extraction protocols for nuclear proteins

  • Include appropriate protease inhibitors to prevent degradation products

  • Consider non-denaturing conditions if epitope recognition requires native conformation

• Detection system issues:

  • For HRP systems: Reduce substrate incubation time and use freshly prepared solutions

  • For fluorescent detection: Include autofluorescence controls and optimize exposure settings

  • Consider signal amplification methods only when target protein is confirmed to be low abundance

When troubleshooting background, implement changes one at a time and document their effects systematically. For EIS1/ICE1 specifically, background can sometimes result from detection of cleaved fragments or alternative isoforms, so size-based verification is essential .

How can I differentiate between true EIS1/ICE1 signal and cross-reactivity with similar proteins?

Differentiating true EIS1/ICE1 signal from cross-reactivity requires a comprehensive validation approach:

• Molecular validation strategies:

  • siRNA/shRNA knockdown: Confirm signal reduction following EIS1/ICE1 depletion

  • CRISPR-Cas9 knockout: Generate complete EIS1/ICE1 knockout controls

  • Overexpression: Correlate signal intensity with controlled expression levels

• Biochemical verification methods:

  • Immunoprecipitation followed by mass spectrometry

  • Sequential immunoprecipitation with antibodies targeting different epitopes

  • Competition assays with recombinant EIS1/ICE1 protein or peptides

• Data analysis approaches:

  • Compare molecular weight with predicted values (248 kDa for human EIS1/ICE1)

  • Evaluate subcellular localization (nuclear localization expected)

  • Co-localization with known interacting partners

• Cross-reactivity assessment:

  • Test antibody against related proteins, particularly other LEC complex components

  • Examine species cross-reactivity systematically to identify potential non-specific binding

  • Use tissue/cell panels to identify unexpected expression patterns

For conclusive validation, combining multiple approaches provides the strongest evidence. For instance, a signal that shows the correct molecular weight, decreases with siRNA treatment, and can be immunoprecipitated and verified by mass spectrometry provides high confidence of specificity .

How can EIS1/ICE1 antibodies be utilized in studying transcriptional regulation mechanisms?

EIS1/ICE1 antibodies enable several sophisticated approaches to investigate transcriptional regulation:

• Chromatin structure and dynamics:

  • ChIP-seq to map genome-wide binding profiles

  • ChIP-qPCR for targeted analysis of snRNA gene occupancy

  • Sequential ChIP (Re-ChIP) to identify co-occupancy with other transcription factors

• Protein-protein interaction networks:

  • Co-immunoprecipitation to identify stable interacting partners

  • Proximity labeling techniques (BioID, APEX) to capture transient interactions

  • FRET or PLA assays to visualize interactions in situ

• Functional transcriptional regulation:

  • ChIP followed by in vitro transcription to assess direct effects on RNA polymerase activity

  • Luciferase reporter assays using promoters identified in ChIP experiments

  • RNA-seq following EIS1/ICE1 depletion to identify regulated genes

• Dynamics of complex assembly:

  • Chromatin fractionation to assess binding under different cellular conditions

  • Live-cell imaging with fluorescently tagged antibody fragments

  • Synchronization experiments to examine cell-cycle specific activities

When designing these experiments, considering the nuclear localization and involvement in multi-protein complexes is essential for proper interpretation. For example, changes in EIS1/ICE1 binding may reflect reorganization of the entire LEC complex rather than independent regulation .

What are the comparative considerations when studying EIS1/ICE1 orthologs across different species?

Cross-species studies of EIS1/ICE1 require careful consideration of evolutionary conservation and divergence:

• Antibody epitope conservation analysis:

  • Perform sequence alignment of target regions across species

  • Test cross-reactivity experimentally rather than relying on predictions

  • Consider developing species-specific antibodies for highly divergent regions

• Functional conservation assessment:

  • Compare subcellular localization patterns across species

  • Evaluate interaction partners to identify conserved complex components

  • Assess complementation through cross-species expression experiments

• Experimental design considerations:

When designing cross-species studies, preliminary validation of antibody cross-reactivity is essential. In cases where commercial antibodies aren't available for a particular species, consider epitope mapping to guide custom antibody development .

How can immunofluorescence and super-resolution microscopy be optimized for EIS1/ICE1 detection?

Advanced microscopy for EIS1/ICE1 visualization requires specific optimization strategies:

• Fixation and permeabilization optimization:

  • Test multiple fixatives: 4% PFA (10 minutes), methanol (-20°C, 10 minutes), or dual fixation

  • Nuclear permeabilization: Triton X-100 (0.2-0.5%, 10 minutes) or digitonin (50 μg/ml, 5 minutes)

  • Antigen retrieval: Citrate buffer (pH 6.0) or Tris-EDTA (pH 9.0) for formalin-fixed samples

• Signal enhancement strategies:

  • Tyramide signal amplification for conventional fluorescence microscopy

  • Quantum dots for improved photostability in long-acquisition imaging

  • Multiple antibody layers (primary + secondary + tertiary) for enhanced detection

• Super-resolution specific considerations:

  • STORM/PALM: Use antibodies conjugated to photo-switchable fluorophores

  • STED: Select fluorophores with appropriate depletion characteristics

  • SIM: Optimize sample thickness and mounting media refractive index

• Co-localization study design:

  • Select markers for nuclear compartments (nucleoli, speckles, etc.)

  • Use spectral unmixing for closely related fluorophores

  • Quantitative co-localization analysis using Pearson's or Mander's coefficients

For EIS1/ICE1 specifically, its nuclear localization means that counterstaining with DAPI is essential, but care must be taken to avoid overlapping emissions that could obscure subnuclear localization patterns. Additionally, Z-stack acquisition is recommended to fully capture the three-dimensional distribution within the nucleus .

How might new antibody-based technologies enhance EIS1/ICE1 research?

Emerging technologies are expanding the capabilities of antibody-based EIS1/ICE1 research:

• Single-cell protein analysis approaches:

  • CyTOF (mass cytometry) for high-dimensional protein profiling

  • Single-cell Western blotting for heterogeneity assessment

  • Microfluidic antibody capture for dynamic measurements

• In situ protein interaction analysis:

  • CODEX multiplexed imaging for spatial interaction mapping

  • Proximity ligation assays for visualizing protein-protein interactions

  • Split-fluorescent protein complementation for live-cell interaction studies

• Dynamic protein tracking technologies:

  • Intrabodies for live-cell tracking of native EIS1/ICE1

  • Nanobodies for improved penetration and reduced interference

  • Optogenetic tagging for controlled localization studies

• Quantitative proteomics integration:

  • Mass spectrometry-based validation of antibody specificity

  • Multiple reaction monitoring for absolute quantification

  • Thermal proteome profiling to assess structural interactions

These advanced technologies can provide unprecedented insights into EIS1/ICE1 function, particularly regarding its dynamic behavior in different cellular states and its specific role within the complex transcriptional machinery of the nucleus .

What are the methodological considerations for studying EIS1/ICE1 post-translational modifications?

Investigating post-translational modifications (PTMs) of EIS1/ICE1 requires specialized approaches:

• PTM-specific antibody selection and validation:

  • Test for specificity against modified vs. unmodified peptides

  • Validate with phosphatase/deacetylase treatments as negative controls

  • Compare detection before and after stimuli known to induce modifications

• Mass spectrometry approaches for PTM mapping:

  • Immunoprecipitation followed by MS/MS analysis

  • Enrichment strategies for specific modifications (TiO₂ for phosphorylation, etc.)

  • Quantitative comparisons across different cellular conditions

• Functional impact assessment:

  • Site-directed mutagenesis of modified residues

  • Phosphomimetic mutations (S/T→D/E) or phospho-null mutations (S/T→A)

  • Correlation of modification state with complex formation and activity

• Temporal dynamics analysis:

  • Synchronization experiments to track cell cycle-dependent modifications

  • Kinase/phosphatase inhibitor studies to identify regulatory enzymes

  • Pulse-chase approaches to determine modification turnover rates

For EIS1/ICE1 specifically, its large size and nuclear localization present challenges for comprehensive PTM mapping. Therefore, a targeted approach focusing on domains involved in protein-protein interactions or DNA binding may be more tractable .

What are the recommended quality control checkpoints when performing EIS1/ICE1 antibody-based experiments?

Implementing a systematic quality control framework ensures reliable EIS1/ICE1 antibody results:

• Pre-experiment validation:

  • Antibody lot testing against positive and negative controls

  • Titration to determine optimal working concentration

  • Specificity verification against recombinant protein when available

• Experimental controls:

  • Positive control (tissue/cell line with known expression)

  • Negative control (knockdown/knockout sample)

  • Technical controls (primary antibody omission, isotype control)

• Analysis quality metrics:

  • Signal-to-noise ratio quantification

  • Reproducibility assessment across technical replicates

  • Comparison with orthogonal detection methods when possible

• Reporting standards checklist:

Adhering to these quality control measures not only improves experimental reproducibility but also facilitates troubleshooting when unexpected results occur .

What is the current consensus on combining EIS1/ICE1 antibody detection with other molecular biology techniques?

Integrating EIS1/ICE1 antibody-based detection with complementary techniques provides comprehensive insights:

• Complementary technique combinations:

  • ChIP-seq + RNA-seq: Correlate binding with transcriptional outcomes

  • Immunoprecipitation + mass spectrometry: Identify interaction partners

  • Immunofluorescence + FISH: Co-localize protein with target genes

• Technical compatibility considerations:

  • Sample preparation harmonization across techniques

  • Sequential application protocols for limited samples

  • Validation of antibody performance in each combined technique

• Integrated data analysis frameworks:

  • Correlation analysis between binding and expression

  • Network analysis incorporating multiple data types

  • Machine learning approaches for pattern identification

• Emerging integrated approaches:

  • Spatial transcriptomics with protein detection

  • Single-cell multi-omics incorporating protein measurements

  • Live-cell analysis combining antibody fragments with genomic tags

For EIS1/ICE1 research specifically, the combination of techniques can help delineate its precise role within the LEC complex and provide mechanistic insights into how it contributes to transcriptional regulation of snRNA genes and potentially other targets .